Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
TELA 
Tela Bio Inc (TELA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: TELA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -44% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 50.23M USD | Price to earnings Ratio - | 1Y Target Price 5.8 |
Price to earnings Ratio - | 1Y Target Price 5.8 | ||
Volume (30-day avg) 356128 | Beta 1.1 | 52 Weeks Range 1.15 - 6.50 | Updated Date 04/1/2025 |
52 Weeks Range 1.15 - 6.50 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.33 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-19 | When Before Market | Estimate -0.222 | Actual -0.23 |
Profitability
Profit Margin -54.61% | Operating Margin (TTM) -47.33% |
Management Effectiveness
Return on Assets (TTM) -31.66% | Return on Equity (TTM) -159.87% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 37053584 | Price to Sales(TTM) 0.72 |
Enterprise Value 37053584 | Price to Sales(TTM) 0.72 | ||
Enterprise Value to Revenue 0.53 | Enterprise Value to EBITDA -5.01 | Shares Outstanding 39551100 | Shares Floating 20538094 |
Shares Outstanding 39551100 | Shares Floating 20538094 | ||
Percent Insiders 8.4 | Percent Institutions 72.47 |
Analyst Ratings
Rating 4.5 | Target Price 9.5 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Tela Bio Inc
Company Overview
History and Background
Tela Bio, Inc. was founded in 2012 and focuses on developing and marketing surgical reconstruction products using its OviTex reinforced tissue matrix (RTM) technology.
Core Business Areas
- Surgical Reconstruction: Develops and markets surgical reconstruction products for hernia repair, abdominal wall reconstruction, and soft tissue reconstruction.
Leadership and Structure
Tela Bio is led by Antony Koblish (CEO). Its organizational structure includes departments for research and development, manufacturing, sales, marketing, and administration.
Top Products and Market Share
Key Offerings
- OviTex Reinforced Tissue Matrix (RTM): A biologic scaffold for soft tissue reconstruction and hernia repair. Market share is estimated at below 5% of the total hernia repair market, competing with synthetic meshes and other biologic meshes. Competitors: Allergan (acquired by AbbVie - ABBV), W.L. Gore & Associates, Becton Dickinson (BDX).
Market Dynamics
Industry Overview
The surgical reconstruction market, including hernia repair, is growing due to aging populations, increasing obesity rates, and advancements in surgical techniques.
Positioning
Tela Bio is positioned as a provider of biologic-based solutions offering potential advantages over synthetic materials in certain applications. They are trying to establish themselves as a significant player in complex abdominal wall reconstruction.
Total Addressable Market (TAM)
The TAM for hernia repair and soft tissue reconstruction is estimated to be in the billions of dollars annually. Tela Bio is targeting a portion of this market with its OviTex RTM technology.
Upturn SWOT Analysis
Strengths
- Proprietary OviTex technology
- Focus on biologic-based solutions
- Potential for improved patient outcomes compared to synthetic meshes
Weaknesses
- Limited market share compared to larger competitors
- Reliance on a single product platform
- Ongoing losses and need for additional funding
Opportunities
- Expanding applications for OviTex technology
- Increasing demand for biologic-based solutions
- Potential for strategic partnerships or acquisitions
Threats
- Competition from established players
- Regulatory challenges
- Risk of product recalls or safety concerns
Competitors and Market Share
Key Competitors
- ABBV
- BDX
- SYK
Competitive Landscape
Tela Bio competes with larger, more established companies in the surgical reconstruction market. Its advantage lies in its proprietary OviTex technology, but its smaller size and limited resources present challenges.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Tela Bio has experienced revenue growth driven by increased adoption of its OviTex technology.
Future Projections: Future growth depends on continued market penetration, new product development, and successful commercialization efforts. Analyst estimates vary.
Recent Initiatives: Recent initiatives include expanding the sales force, launching new products, and conducting clinical studies.
Summary
Tela Bio is a smaller company in the surgical reconstruction market showing revenue growth but also ongoing losses. The OviTex technology is a key differentiator, but competition is fierce, and continued funding is crucial. They have the potential to make a name for themselves, but need to overcome the challenges of profitability.
Similar Companies
ABBV
AbbVie Inc
ABBV
AbbVie Inc
BDX
Becton Dickinson and Company
BDX
Becton Dickinson and Company
SYK
Stryker Corporation
SYK
Stryker Corporation
Sources and Disclaimers
Data Sources:
- Tela Bio Inc. SEC Filings
- Analyst Reports
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is based on estimates and may vary. Investment decisions should be made based on individual circumstances and after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tela Bio Inc
Exchange NASDAQ | Headquaters Malvern, PA, United States | ||
IPO Launch date 2019-11-08 | Co-founder, President, CEO & Director Mr. Antony Koblish | ||
Sector Healthcare | Industry Medical Devices | Full time employees 209 | Website https://www.telabio.com |
Full time employees 209 | Website https://www.telabio.com | ||
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.